344 related articles for article (PubMed ID: 15976038)
1. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
4. The hERG channel activator, RPR260243, enhances protective
Shi YP; Pang Z; Venkateshappa R; Gunawan M; Kemp J; Truong E; Chang C; Lin E; Shafaattalab S; Faizi S; Rayani K; Tibbits GF; Claydon VE; Claydon TW
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H251-H261. PubMed ID: 32559136
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
6. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
7. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
8. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
9. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
Kiehn J; Lacerda AE; Wible B; Brown AM
Circulation; 1996 Nov; 94(10):2572-9. PubMed ID: 8921803
[TBL] [Abstract][Full Text] [Related]
10. Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide.
Lee K; Park JB; Jeon BH; Kim KJ; Ryu PD; Kwon LS; Kim HY
J Cardiovasc Pharmacol; 2003 Nov; 42(5):648-55. PubMed ID: 14576514
[TBL] [Abstract][Full Text] [Related]
11. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
Perry M; Sachse FB; Sanguinetti MC
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13827-32. PubMed ID: 17693551
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
14. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
Perry M; Sachse FB; Abbruzzese J; Sanguinetti MC
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20075-80. PubMed ID: 19892732
[TBL] [Abstract][Full Text] [Related]
15. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
16. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.
Kiesecker C; Zitron E; Lück S; Bloehs R; Scholz EP; Kathöfer S; Thomas D; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):423-35. PubMed ID: 15599706
[TBL] [Abstract][Full Text] [Related]
17. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
18. A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.
Perry M; Sanguinetti MC
Mol Pharmacol; 2008 Apr; 73(4):1044-51. PubMed ID: 18162604
[TBL] [Abstract][Full Text] [Related]
19. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A receptor agonist, on native IKr and cloned HERG current.
Saegusa N; Sato T; Ogura T; Komuro I; Nakaya H
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):492-9. PubMed ID: 15558241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]